<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122784</url>
  </required_header>
  <id_info>
    <org_study_id>rF1V-02b</org_study_id>
    <nct_id>NCT01122784</nct_id>
  </id_info>
  <brief_title>Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant</brief_title>
  <official_title>A Phase 2b Randomized, Single-Blinded Study to Evaluate the Safety and Immunogenicity of 80 µg Recombinant Plague Vaccine (rF1V) With and Without Adjuvant at Two Vaccination Schedules in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DynPort Vaccine Company LLC, A GDIT Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DynPort Vaccine Company LLC, A GDIT Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, randomized, single-blinded comparison of two formulations of the rF1V vaccine at&#xD;
      a single dosage of 80 µg and two 3-dose schedules in 400 healthy, adult volunteers in four&#xD;
      parallel cohorts. Two rF1V vaccine cohorts (N=160 each) and two rF1V antigen-only cohorts&#xD;
      (N=40 each) will be vaccinated at two different three-dose schedules (Days 0, 56 and 182 or&#xD;
      Days 0, 56 and 121).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this trial are: to compare the safety of rF1V vaccine administered in two&#xD;
      different schedules through 28 days after each vaccination and cumulatively to Day 210; to&#xD;
      compare the immunogenicity of rF1V vaccine administered in two different schedules through 28&#xD;
      days after Vaccination 3; to compare the safety and immunogenicity of rF1V vaccine&#xD;
      administered by two different schedules through 12 months after Vaccination 3; and to assess&#xD;
      the contribution of the adjuvant to the immunogenicity of the rF1V antigen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure frequency and severity of local and systemic adverse events (AEs) through 28 days after each vaccination and cumulatively through Day 210.</measure>
    <time_frame>Day 210 for Cohorts 1 through 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the frequency and severity of local and systemic AEs of rF1V vaccine with and without adjuvant administered at 2 dosing schedules.</measure>
    <time_frame>Through Day 540 for Cohort 1 and 2 and Day 485 for Cohorts 3 and 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the proportion of volunteers in each cohort demonstrating seroconversion to vaccine antigens and the magnitude of the immune response.</measure>
    <time_frame>Through Day 540 for Cohort 1 and 2 and Day 485 for Cohorts 3 and 4.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Plague Vaccine</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 182</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 182</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 121</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 121</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rF1V vaccine (with Adjuvant)</intervention_name>
    <description>80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Recombinant Plague Vaccine rF1V</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rF1V vaccine (without Adjuvant)</intervention_name>
    <description>80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Recombinant Plague Vaccine rF1V without Adjuvant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rF1V vaccine (with Adjuvant)</intervention_name>
    <description>80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Recombinant Plague Vaccine rF1V</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rF1V vaccine (without Adjuvant)</intervention_name>
    <description>80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Recombinant Plague Vaccine rF1V without Adjuvant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The volunteer has signed the ICF and the HIPAA authorization and has successfully&#xD;
             completed (at least 90% correct) the Test of Understanding.&#xD;
&#xD;
          2. The volunteer is a male or female 18 to 55 years of age (inclusive) at the time of the&#xD;
             screening visit.&#xD;
&#xD;
          3. The volunteer is in good health as determined by the screening physician based upon&#xD;
             medical history and physical examination, including vital signs within acceptable&#xD;
             ranges.&#xD;
&#xD;
          4. The volunteer has acceptable ranges for the laboratory parameters.&#xD;
&#xD;
          5. The volunteer has no clinically significant abnormalities on ECG.&#xD;
&#xD;
          6. The volunteer agrees not to donate blood, plasma or blood components for therapeutic&#xD;
             or research purposes, except to meet requirements of this study, at any time during&#xD;
             the course of the study.&#xD;
&#xD;
          7. The volunteer is willing to have his or her blood samples stored for future plague&#xD;
             research studies.&#xD;
&#xD;
          8. The volunteer is willing to comply with the requirements of the protocol through the&#xD;
             end of the study.&#xD;
&#xD;
          9. Female volunteers must be of non-childbearing potential or, if of childbearing&#xD;
             potential, must not be pregnant or lactating and must use acceptable contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of plague exposure or disease or previous vaccination with any plague vaccine.&#xD;
&#xD;
          2. History of allergy to kanamycin or other aminoglycosides (e.g., gentamicin,&#xD;
             tobramycin, amikacin).&#xD;
&#xD;
          3. History of anaphylaxis or other serious adverse reactions to vaccines or aluminum.&#xD;
&#xD;
          4. Active tuberculosis or other systemic infectious process by review of systems and PE.&#xD;
&#xD;
          5. History of chronic illness requiring continuous or frequent medical intervention or&#xD;
             acute/chronic untreated conditions, multiple sclerosis, immunodeficiency, autoimmune&#xD;
             or immunosuppressive disease or use of immunosuppressive medications.&#xD;
&#xD;
          6. Diabetes mellitus of any type requiring treatment with insulin or oral hypoglycemic&#xD;
             drugs.&#xD;
&#xD;
          7. History of chronic, severe or recurrent joint pain (four or more clinically&#xD;
             significant occurrences per year requiring treatment for remission) or arthritis of&#xD;
             any etiology other than osteoarthritis.&#xD;
&#xD;
          8. Previous diagnosis of any serious psychiatric disorder.&#xD;
&#xD;
          9. Acute illness, evidence of significant active infection or evidence of systemic&#xD;
             disease at the time of enrollment.&#xD;
&#xD;
         10. Oral temperature &gt; 99.5°F.&#xD;
&#xD;
         11. Receipt of chemotherapeutic and immunosuppressive agents, including high-dose systemic&#xD;
             glucocorticoids (i.e., prednisone-equivalent dose of &gt; 20 mg/day).&#xD;
&#xD;
         12. Receipt of blood, any blood product or immune globulin.&#xD;
&#xD;
         13. Receipt of any investigational drug therapy or investigational implantable device or&#xD;
             intent to receive any other investigational drug therapy or device throughout their&#xD;
             study participation.&#xD;
&#xD;
         14. Receipt of any investigational vaccine.&#xD;
&#xD;
         15. Receipt or intent of any licensed nonliving vaccine.&#xD;
&#xD;
         16. Receipt of any licensed live vaccine within 60 days before Vaccination 1&#xD;
&#xD;
         17. Donation of more than 400 mL of blood 8 weeks before Vaccination 1.&#xD;
&#xD;
         18. Occupational or other responsibilities that would prevent completion of participation&#xD;
             in the study.&#xD;
&#xD;
         19. Weight or body mass index (BMI) outside acceptable ranges.&#xD;
&#xD;
         20. Positive screening laboratory test for HIV antibody, HCV antibody or HBsAg.&#xD;
&#xD;
         21. A positive result on a urine drug screen that tests for common substances of abuse.&#xD;
&#xD;
         22. Female volunteer is pregnant or lactating.&#xD;
&#xD;
         23. The volunteer is currently on active duty in the U.S. military, or a member or&#xD;
             relative of the clinical site study staff.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Saviolakis, MD</last_name>
    <role>Study Director</role>
    <affiliation>DynPort Vaccine Company, a CSC Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Research Institute</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clinical Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Reseach Assoicates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WRAIR Clinical Trials Center</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pharmceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 7, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <disposition_first_submitted>August 14, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 14, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 22, 2013</disposition_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plague</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plague</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

